Minimal differences seen in yearly number of injections and cost for ranibizumab, aflibercept

ORLANDO, Fla. — Differences between ranibizumab and aflibercept for treatment of neovascular age-related macular degeneration were minimal in annual injection frequency, costs and number of ophthalmologist visits, according to a study presented at the Association for Research in Vision and Ophthalmology meeting. Furthermore, a higher rate of endophthalmitis was associated with aflibercept injections, Szilárd Kiss, MD, and colleagues said in the poster.

Full Story →